

FINAL REPORT ON THE SAFETY ASSESSMENT OF SODIUM ALPHA-OLEFIN SULFONATES¹

Sodium C₁₄₋₁₆ Olefin Sulfonate, Sodium C₁₂₋₁₄ Olefin Sulfonate, Sodium C₁₄₋₁₈ Olefin Sulfonate, and Sodium C₁₆₋₁₈ Olefin Sulfonate are the Sodium α -Olefin Sulfonates used in cosmetics as surfactant-cleansing agents. The highest concentration reportedly is 16% in shampoos and bath and shower products. These ingredients are a mixture of long-chain sulfonate salts prepared by sulfonation of α -olefins of various carbon chain lengths noted as subscripts. In the manufacture of these ingredients, delta and gamma sultones may be produced. Sodium α -Olefin Sulfonates are poorly absorbed through normal skin, but are significantly absorbed through damaged skin. Acute oral LD₅₀ values were 1.3–2.4 g/kg in rats and 2.5–4.3 g/kg in mice. Short-term toxicity studies using rats showed no consistent effects, even with exposures in the 0.5–1.0 g/kg range. Concentrations above 10% produced moderate ocular irritation and a concentration of 5% produced mild ocular irritation in rabbits. In reproductive and developmental toxicity studies, fetal abnormalities were noted, but only at doses that were maternally toxic. Genotoxicity data were mostly negative and oral and dermal carcinogenicity studies were negative. Various animal and clinical studies found irritation and sensitization. Sensitization was attributed to low level gamma sultone residues. Because gamma sultones are demonstrated sensitizers at very low levels, it was concluded that any product containing Sodium α -Olefin Sulfonates should have very little gamma sultone residues. The gamma sultone levels should not exceed 10 ppm for saturated (alkane) sultones, 1 ppm for chloro-sultones, and 0.1 ppm for unsaturated sultones. Sodium α -Olefin Sulfonates are otherwise considered safe for use in rinse-off products. Based on concerns about irritation, were Sodium α -Olefin Sulfonates to be used in leave-on products, it was concluded that concentrations should not exceed 2% for such uses.


Sodium α -Olefin Sulfonates are long-chain sulfonic acids which function as surfactants-cleansing agents. The following report is a compilation of experimental data concerning the safety of Sodium C₁₄₋₁₆ Olefin Sulfonate (CAS No. 68439-57-6); Sodium C₁₂₋₁₄ Olefin Sulfonate; Sodium C₁₄₋₁₈ Olefin Sulfonate; and Sodium C₁₆₋₁₈ Olefin Sulfonate (CAS No. 68815-15-6) which are the sodium alpha-olefin sulfonates used in cosmetics. Much of the information comes from an evaluation of α -Olefin Sulfonates (AOS) done for the Soap and Detergent Association (Arthur D. Little, Inc. 1993).

Received 1 May 1998; accepted 10 July 1998.

¹Reviewed by the Cosmetic Ingredient Review Expert Panel. Bindu Nair, Scientific Analyst and Writer, prepared this report. Address correspondence to her at Cosmetic Ingredient Review, 1101 17th Street, NW, Suite 310, Washington, DC 20036, USA.



sodium 3-hydroxyalkane sulfonate



sodium 2,3-alkene sulfonate

Figure 1. Chemical formulae for sodium hydroxyalkane and sodium alkane sulfonates.

CHEMISTRY

Definition and Structure

By definition, olefins are alkenes (unsaturated aliphatic hydrocarbons) obtained by cracking naphtha or other petroleum fractions at high temperatures. Alpha-olefins are particularly reactive because the double bond of the alkene is on the first carbon of the chain (Lewis 1993). Sodium AOS is a mixture of long chain sulfonate salts prepared by sulfonation of C(x-y) alpha-olefins where (x-y) represents the range of the carbon chain length (Wenninger and McEwen 1995a; 1995b). The mixture consists primarily of sodium hydroxyalkane sulfonates and sodium alkene sulfonates as shown in Figure 1 (Wenninger and McEwen 1995b; Arthur D. Little, Inc. 1993). Sodium C₁₄₋₁₆ AOS is identified in Japan as sodium tetradecenesulfonate or sodium tetradecenesulfonate solution (Rempe and Santucci 1992).

Method of Manufacture

Although alpha-olefins can be produced by cracking of paraffin wax as noted, the limited availability of waxy crudes prevents large-scale use of the technique. For industrial use, α -olefins are synthesized by oligomerization of ethylene (Schoenberg 1980). Using continuous falling film techniques, the α -olefins are sulfonated with gaseous sulfur trioxide; typically a sulfur trioxide:olefin molar ratio between 1.0 to 1.2 is used. The sulfonation produces alkenylsulfonic acid and intermediate sultones as well as other by-products. At this stage of the process, the sultone content increases at the expense of alkylsulfonic acid upon standing. If the mixture ages too long, 1,4-sultone may be produced;

it is more difficult to hydrolyze than either 1,2 or 1,3-sultone (Kirk-Othmer 1983). The continuous falling film process limits contact time, temperature, molar ratio, and feed rates to eliminate undesirable side products formed during residence time (Schoenberg 1980). The acidic reaction mixture is neutralized and then hydrolyzed with an excess of sodium hydroxide to saponify the intermediate alkane sultones (some of which may be mild skin sensitizers) (Roberts and Williams 1983). The conditions of hydrolysis determine whether hydroxyalkane sulfonates or alkene sulfonates are the favored products. The process yields AOS mixtures of 60–65% alkene sulfonates, 30–35% hydroxyalkane sulfonates, and 5–10% disulfonates. Roberts et al. (1987) stressed that hypochlorite bleach should not be used in the manufacture of the Sodium AOS so as to avoid producing certain unsaturated and chlorosultones as by-products. These compounds are undesired by-products as they have been demonstrated to be highly potent skin sensitizers (Connor et al. 1975; Ritz, Connor, and Sauter 1975; Goodwin et al. 1983; see also Table 2). According to Ter Haar (1983), since 1973 the bleaching step in the production of AOS has been carried out at high pH to avoid the formation of hypochlorous acid (which subsequently reacts with alkene sulfonates to form chloro gamma and delta sultones), confirming the view of Roberts and Williams (1983) that knowledge of the chemistry of sultone formation allows them to be avoided in the manufacture of AOS.

Impurities

Stepan Company (1995) reports their internal specifications for Sodium AOS include a 31 ppm maximum for 1,4-sultones (delta sultones).

Techniques for sultone detection include separating and concentrating sultones from the surfactant via thin layer chromatography (TLC) followed by high performance liquid chromatography (HPLC) quantification. This technique has a sensitivity of 0.1 ppm and can go as low as 0.01 ppm when background does not interfere (MacMillan and Wright 1977). Another technique uses preparative HPLC followed by gas chromatography–mass spectrometry (GC–MS) and has a sensitivity of 2 ppb (Matsutani et al. 1986).

USE

Cosmetic

Sodium α -Olefin Sulfonates are used in cosmetic formulations as a surfactant–cleansing agent (Wenninger and McEwen 1995b). Data from the FDA (1996) indicates that Sodium C_{14–16} Olefin Sulfonate was used

Table 1. Reported use of Sodium C₁₄₋₁₆ Olefin Sulfonate (FDA 1996)

Product category	No. formulations in category	No. containing ingredient
Bath oils, tablets and salts	147	1
Bubble baths	211	17
Other bath preparations	166	7
Rinses (noncoloring)	60	1
Shampoos (noncoloring)	972	26
Other hair coloring preparations	71	1
Other manicuring preparations	83	1
Bath soaps and detergents	372	22
Other personal cleanliness	339	3
Cleansing	820	13
Paste masks (mud packs)	300	1
1996 Total		93

in a total of 93 products (Table 1). There were no reported uses of the other three Sodium AOS. Concentrations of use are no longer reported to the Food and Drug Administration (FDA) (FDA 1992). However, data provided directly to CIR from the cosmetics industry indicate the following as the highest Sodium Olefin Sulfonates concentration used: 5% in cleansers and 16% in shampoos and bath and shower products. Data from industry specifically on Sodium C₁₄₋₁₆ Olefin Sulfonates indicate use at 3.6% in facial cleansing foams; >5-10% in skin care preparations; and >10% in personal cleanliness products (CTFA 1995).

International

Sodium C₁₄₋₁₆ AOS is listed in the *Japanese Comprehensive Licensing Standards of Cosmetics by Category (CLS)*. Sodium tetradecenesulfonate which conforms to the specifications of the Japanese Standards of Cosmetic Ingredients can be used without restrictions in all CLS categories except eyeliners and lipsticks and lip creams. Sodium tetradecenesulfonate solution which conforms to the standards of the *Japanese Cosmetic Ingredient Codex* can be used without restrictions in all CLS categories except eyeliners and lipsticks and lip creams, dentifrices and bath preparations (Yakuji Nippo, Ltd. 1994).

Noncosmetic

AOS and the ammonium, calcium, magnesium, potassium and sodium salts are approved by the FDA for use as indirect food additives. The

ruling specifies that the alkyl group be in the range of C₁₀₋₃₈ with not less than 50% being in the range of C₁₄₋₁₆ (Rothschild 1990).

GENERAL BIOLOGY

Absorption, Distribution, Metabolism and Excretion

Oral

In a metabolism study, ¹⁴C-AOS was administered as a single oral dose of 100 mg (50 μCi)/kg to three male Wistar rats. The radioactive AOS was a mixture of approximately 55% sodium 3-hydroxy alkane sulfonate [C₁₁H₂₃CH(OH)CH₂¹⁴CH₂SO₃Na] and 45% sodium alkenyl(2) sulfonate [C₁₁H₂₃CH=CH¹⁴CH₂SO₃Na]. The mixture was rapidly absorbed from the gastrointestinal tract (80% absorption) with peak activity in the blood at 3 hours after dosing. Within 12 hours, radioactivity in the bile accounted for 4.3% of the dose. At 24 hours postdosing, approximately 0.08% of the administered AOS was detected in the cecal content; the concentrations in other tissues were less than 0.02% dose/g. At that time, 72% of the dose had been excreted in the urine and 22% in the feces. No intact ¹⁴C-AOS was detected in the urine. A metabolite more polar than AOS was detected (polarity determined by electrophoresis and equilibrium dialysis). The researchers suggested the metabolite was a hydroxylated or polyhydroxylated sulfonic acid with a shorter chain length than AOS (Inoue, O' Grodnick, and Tomizawa 1982).

Parenteral

Inoue, O' Grodnick, and Tomizawa (1982) conducted an intravenous metabolism study using the radioactive AOS described above. A single dose of 10 mg (5 μCi)/kg was administered to three male Wistar rats. Within 1 hour, half of the administered dose was excreted. By 6 hours postdosing, 90% of the administered dose had been eliminated. The concentrations of intact AOS in the liver and kidneys were comparable with blood concentrations. Therefore, the researchers proposed that, "intact AOS is distributed to about the same degree as the blood concentration in tissues." Similar to results from the oral studies, no intact AOS was detected in the urine. Because the concentration of the metabolites increased with time, the researchers proposed, "intact ¹⁴C-AOS was metabolized in tissues, and therefore the transfer rate of metabolites from tissue to blood seems to be slightly slower than in urinary excretion rate." The researchers considered AOS to be rapidly absorbed and metabolized and the products excreted in the urine.

Dermal

The percutaneous absorption of ^{14}C -AOS in rats was investigated by Minegishi, Osawa, and Yamaha (1977). [The AOS was of the same composition and the radioisotopes at the same sites as in the study by Inoue, O' Grodnick, and Tomizawa (1982).] The solution was applied to the dorsal skin of groups of three male Wistar rats. The treatment groups were as follows: (1) intact skin dried naturally after application; (2) intact skin wiped off 0.5 hour after application; (3) intact skin wiped off 1.5 hour after application; (4) intact skin with a plastic cup containing the test substance (for continuous exposure); and (5) damaged skin (without stratum corneum) dried naturally. In the groups where the applied AOS was wiped off after a specified time (Groups 2 and 3), 60–70% of the applied radioactivity was recovered in the removal of the surfactant with wet cotton balls. Animals were killed at 24 hours. When 0.5 ml of a 0.2% ^{14}C -AOS solution was applied to the animals of Group 1, 0.33% was recovered in the urine, 0.08% in the bile, and 0.21% in the main organs 24 hours after application. It was estimated that 0.6% of the applied dose had been absorbed. Comparing results of Groups 1, 2, and 3, it was determined that the dermal absorption was almost complete by 1.5 hours postapplication. The excretion in the urine and bile approached the highest rate around 3 hours after application; excretion then decreased, but was still detectable at 70–90 hours postapplication. When the 0.2% dose was applied for continuous contact (Group 4), a small amount continued to be absorbed. In contrast, in damaged skin (Group 5), 36.26% of the applied dose was recovered in the urine, 1.83% in the bile, and 12.28% in the major organs 30 hours after application. Thus, 50% of the applied dose had been absorbed.

ANIMAL TOXICOLOGY

Oral Toxicity

Acute

Oral LD_{50} values for AOS range from 1300–2400 mg/kg in rats and 2500–4300 mg/kg in mice (Arthur D. Little, Inc. 1993). Ter Haar (1983) reported six samples of 36.9% C_{14-16} AOS had an average LD_{50} (rats) of 4000 mg/kg.

Short-Term

Rats were fed diets containing 0.625, 1.25, or 1.5% AOS (70% C_{14} : 30% C_{16}) for 7 days. At concentrations of 1.25 and 2.5%, a slight increase in the liver to body weight ratio was noted in males; at the 2.5% dose, a significant body weight depression was noted for 2 days in males and for

7 days in females. The "no effect" dosage was between 0.625 and 1.25% (Arthur D. Little, Inc. 1993).

In a 90-day feed study, groups of rats (number not specified) received AOS at doses of 40, 200, or 1,000 mg/kg/day. The AOS sample (89.7% active) contained 1.5% sultones and had been bleached and dried. A slight increase in the liver : body weight ratio was observed in animals of the high-dose group. No other changes in hematologic or biochemical parameters, feed consumption, gross or microscopic lesions were noted (Arthur D. Little, Inc. 1993).

In a 91-day feed study, groups of rats (number not specified) received C₁₄₋₁₆ AOS (34% active) at doses of 50, 150, or 500 mg/kg. No treatment-related toxic or histopathologic changes were observed. Anomalies were noted in hematologic parameters. No further details were given. However, it was reported that similar changes were noted in rats which received C₁₆₋₁₈ AOS (34% active) at doses of 50, 150, or 500 mg/kg also for 91 days. In that study red blood cell counts, but not hematocrit or hemoglobin values, were significantly higher for females of the high-dose group. Increased hemoglobin and hematocrit values were noted in females of the 150 mg/kg group, and significantly higher hematocrit values were noted in males of the 50 mg/kg AOS group (Arthur D. Little, Inc. 1993).

Acute Dermal Toxicity

Arthur D. Little, Inc. (1993) reported the following unpublished dermal LD₅₀ values: two studies testing C₁₄₋₁₆ AOS in rabbits, 1,130 mg/kg and 2,150 mg/kg, respectively; undiluted C₁₄₋₁₈ AOS, 578 mg/kg. Ter Haar (1983) reported 36.9% C₁₄₋₁₆ AOS had a dermal LD₅₀ in rabbits of >6000 mg/kg.

Inhalation Toxicity

Acute

Groups of ten rats were exposed for 1 hour to a powdered aerosol of either C₁₄₋₁₆ AOS flake (90% active) or a spray-dried formulation containing 17% C₁₄₋₁₆ AOS at concentrations of 229 mg/L and 221 mg/L, respectively. No information regarding particle size was provided. All rats survived exposure and appeared normal clinically except for an increase in preening behavior. Five rats were killed and examined; mild petechial hemorrhages were noted in two animals exposed to the flake and in one animal exposed to the spray-dried formulation. The remaining animals were killed after 14 days; no treatment-related changes were noted at necropsy (Arthur D. Little, Inc. 1993).

Short-Term

Groups of 40 rats survived 20, 6-hour exposures (in 30 days) to either 0.9 or 10% C₁₄₋₁₆ AOS flake (90% active). In the 0.9% group, no changes from control values were noted with respect to body weight, feed intake, blood chemistry, and gross lesions. At the 10% exposure level, a significant increase in gastric lesions was noted with 19/40 rats having edema and acute inflammation cell infiltration and 13/40 having ulceration of the squamous mucosa. The researchers attributed the lesions to stress factors (Arthur D. Little, Inc. 1993).

Ocular Irritation

Arthur D. Little, Inc. (1993) cited an unpublished report in which 1% AOS was not an ocular irritant to rabbits. At 5%, AOS was mildly to severely irritating and produced corneal necrosis. Imori, Ogata, and Kudo (1972a, b) reported 5% C₁₄₋₁₉ AOS was mildly irritating. The review by the Soap and Detergent Association states that "there is general agreement that higher concentrations (10-40% of AOS) are moderately to severely irritating to rabbit eyes."

Using the Draize scoring system, two studies classified a 71.28% effective concentration of AOS in formulation (the formulation contained 79.2% of 90% AOS) as a moderate ocular irritant when tested on six rabbits (CTFA 1981).

Dermal Irritation

Acute

Referring to acute dermal irritation studies, Arthur D. Little, Inc. (1993) states "the majority of data concerned with the dermal irritation of AOS show it to be slightly to severely irritating to rabbit skin." In tests done on 20 AOS samples (of varying and sometimes similar carbon chain lengths), three AOS samples were classified as primary irritants according to the Draize procedure. These instances were as follows: a 25.7% C₁₆₋₁₈ AOS sample had a Primary Irritation Index (PII) of 6.6 (maximum possible score is 8.0); a 10% sample of C₁₆₋₁₈ AOS had a PII of 8.0; and a sample of 35% C₁₇₋₂₀ AOS had a PII of 4.6. However, the results have varied from sample to sample and from study to study. For example, 10% sample of C₁₄₋₁₆ AOS had a score of 6.2 in one assay (primary irritant), whereas another assay, using a sample from another manufacturer, had a score of 1.0 (slight irritant). The review stated, "such factors as AOS purity, method of production and/or variations in experimental technique may account for this inconsistency."

Repeated Exposure

Arthur D. Little, Inc. (1993), cites five unpublished studies that tested the dermal toxicity and irritation potential of AOS. In one study, 10 applications (in 14 days) of either 0.5 or 1.0% AOS produced no irritancy or skin fatigue in rabbits. In another study, 2 ml/kg/day of a 5% aqueous solution of AOS (34% active) was applied to the backs of six rabbits for 91 days. Mild to moderate skin irritation was noted (nonsuppurative dermatitis, parakeratosis, hyperkeratosis). One rabbit had a firm, swollen salivary gland which had changes of inflammation and hyperplasia. In the third study, twice daily application of open patches containing 2% aqueous C₁₆₋₁₈ or C₁₂ AOS (nine applications total) resulted in nil-to-slight and slight-to-moderate cumulative skin irritation in guinea pigs, respectively. In the fourth study, a 28-day dermal exposure to either 1% aqueous C₁₄₋₁₆ AOS or a formulation containing 1% AOS produced no effect on intact rabbit skin. Questionable exfoliation and hyperemia were observed on abraded skin. The number of animals used was not reported. In the fifth study, an epilated guinea pig received two, 4-hour applications (24 hours apart) of either 2.4% AOS in a detergent or 8% aqueous C₁₅₋₁₈ AOS. Both solutions were mildly irritating. Another dilution of the detergent (effective AOS concentration of 3.6%) was moderately irritating.

Dermal Sensitization

Table 2 lists guinea pig sensitization studies done on various sultones.

Arthur D. Little, Inc. (1993) cites unpublished studies regarding the sensitization potential of AOS. In one guinea pig assay, hydroxyalkane sulfonate C₁₂₋₁₈ (21% active) and alkene sulfonate C₁₂₋₁₈ (21% active), both used in the production of AOS, were nonsensitizers. The review states that commercial AOS should not contain unsaturated and chloro-1,3-sultones which are potent sensitizers, but may contain small amounts of alkane 1,4-sultones.

Ter Haar (1983) found that no sensitization occurred when guinea pigs were exposed to small amounts of C₁₄ or C₁₆ alkane 1,4-sultone. However, sensitization occurred in 50–60% of the animals when a sample with a 2% C₁₄ 1,3-sultone content was used. Table 2 lists guinea pig sensitization studies done on various sultones.

Arthur D. Little, Inc. (1993) cites eleven unpublished studies which tested 64 AOS samples mostly derived from C₁₄₋₁₈ α -olefins. Fifty-five of the samples were nonsensitizers. Of the nine sensitizers, two were photosensitizers. These latter two samples were a 44% active AOS paste (sensitized 6/6 animals) and an 80.7% active spray-dried AOS powder (sensitized 4/6 animals). Another two of the nine were aged samples;

Table 2. Guinea pig sensitization studies on sultones (Arthur D. Little, Inc. 1993)

No.	Sultone type	Concentration (ppm)	Sensitization rate	Comment/technique	Reference	
<i>Unsubstituted alkane 1,4-sultones (delta)</i>						
1.	C ₁₆ 1,4-sultone	Injection: Topical: Challenge:	10,000 (1%) 50,000 (5%) 5,000 (0.5%)	zero	Magnusson-Kligman (induction includes injection and topical exposure; challenge topical)	Ter Haar 1983
2.	C ₁₆ 1,4-sultone	Injection: Topical: Challenge:	20,000 (2%) 100,000 (10%) 10,000 (1%)	zero	Magnusson-Kligman	Ter Haar 1983
3.	C ₁₄ 1,4-sultone	Injection: Topical: Challenge:	20,000 (2%) 100,000 (10%) 10,000 (1%)	zero	Magnusson-Kligman	Ter Haar 1983
4.	C ₁₄ 1,4-sultone	Injection: Challenge:	20,000 (2%) 100,000 (10%)	zero		Ter Haar 1983
5.	C ₁₄ 1,4-sultone (2% 1,3-sultone)	Injection: Topical: Challenge:	20,000 (2%) 100,000 (10%) 10,000 (1%)	48%	Magnusson-Kligman	Ter Haar 1983
6.	C ₁₄ 1,4-sultone (2% 1,3-sultone)	Injection: Topical: Challenge:	20,000 (2%) 100,000 (10%) 10,000 (1%)	60%	Magnusson-Kligman	Ter Haar 1983
7.	Dodecane-1,4-sultone	Injection: Challenge: Rechallenge:	18,000 (1.8%) 10,000 (1%) 1,000 (0.1%) 10,000 (1%)	7/11 1/11 2/7	Injection	CTFA 1995b

Unsubstituted alkane, 1,3-sultones (gamma)

8.	C ₁₄ 1,3-sultone	Injection:	20,000 (2%)		Magnusson-Kligman	Ter Harr 1983
		Topical:	100,000 (10%)			
		Challenge:	5,000 (0.5%)	24%		
9.	C ₁₄ 1,3-sultone	Injection:	20,000 (2%)		Magnusson-Kligman	Ter Harr 1983
		Topical:	100,000 (10%)			
		Challenge:	10,000 (1%)	zero		
10.	Dodecane 1,3-sultone	Induction:	22,000 (2.2%)		Injection	CTFA 1995b
		Challenge:	10,000 (1%)	14/15		
			1,000 (0.1%)	7/15		
		Rechallenge:				
		Dodecane-sultone:	10,000	1/14		
		1-Dodecene-sultone:	100	13/14		

Chlorosultones

11.	3-Chlorotetra-decane-1,4-sultone (delta)	Injection:	20 (0.002%)		Magnusson-Kligman	Ter Harr 1983
		Topical:	100 (0.01%)			
		Challenge:	10 (0.001%)	zero		
12.	2-Chlorotetra-decane-1,3-sultone (gamma)	Injection:	20 (0.002%)		Magnusson-Kligman	Ter Harr 1983
		Topical:	100 (0.01%)			
		Challenge:	10 (0.001%)	50%		
13.	2-Chloro-1,3-dodecane sultone (gamma)	Induction:	20 (0.002%)		Injection	CTFA 1995b
		Challenge:	110 (0.011%)	12/13		
			11 (0.0011%)	7/13		
				1.1	4/13	
14.	2-Chloro-1,3-dodecane sultone (gamma)	Induction:	4,000 (0.4%)		Closed patch	CTFA 1995b
		Challenge:	120 (0.012%)	6/14		
				12	5/14	
				1.2	2/14	

(Continued on next page)

Table 2. Guinea pig sensitization studies on sultones (Arthur D. Little, Inc. 1993) (*continued*)

No.	Sultone type	Concentration (ppm)	Sensitization rate	Comment/technique	Reference
<i>Unsubstituted alkane, 1,3-sultones (gamma)</i>					
15.	1-Dodecene-1,3-sultone	Induction: 20 (0.002%) Challenge: 100 (0.01%)	29%		Ter Haar 1983
16.	1-Tetradecene-1,3-sultone	Injection: 20 (0.002%) Topical: 100 (0.01%) Challenge: 10 (0.001%)	42%	Magnusson-Kligman	Ter Haar 1983
17.	1-Tetradecene-1,3-sultone	Induction: 100 Challenge: 100 Rechallenge: 1	10/15 0/15	Magnusson-Kligman same concentration used for both (injection and topical) induction exposures	Inveresk Research International 1985
18.	1-Tetradecene-1,3-sultone	Induction: 100 Challenge: 1 Rechallenge: 0.1	11/15 0/15	Magnusson-Kligman same concentration used for both (injection and topical) induction exposures	Inveresk Research International 1985
19.	1-Tetradecene-1,3-sultone	Induction: 50 Challenge: 10 Rechallenge: (In acetone) 8 (In 5% AOS soln) 1	0/15 13/15	Magnusson-Kligman same concentration used for both (injection and topical) induction exposures	Inveresk Research International 1985
20.	1-Tetradecene-1,3-sultone	Induction: 50 Challenge: 5 Rechallenge: (In acetone) 5 (In 5% AOS soln) 1	15/15 0/15 0/15	Magnusson-Kligman same concentration used for both (injection and topical) induction exposures	Inveresk Research International 1985

21.	1-Tetradecene-1,3-sultone	Induction: Challenge: (In acetone)	1 50 5	8/15; 3/15	Magnusson-Kligman same concentration used for both (injection and topical) induction exposures	Inveresk Research International 1985
22.	1-Tetradecene-1,3-sultone	Induction: Challenge: (In acetone)	0.1 50 5	0/15; 0/15	Magnusson-Kligman same concentration used for both (injection and topical) induction exposures	Inveresk Research Internaotinal 1985
23.	1-Tetradecene-1,3-sultone	Induction: Challenge: (In acetone)	0.01 50 5	0/15; 0/15	Magnusson-Kligman same concentration used for both (injection and topical) induction exposures	Inveresk Research International 1985
24.	1-Tetradecene-1,3-sultone	Induction: Challenge: (In acetone)	0.001 50 5	0/15; 0/15	Magnusson-Kligman same concentration used for both (injection and topical) induction exposures	Inveresk Research International 1985
25.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS sample)	Induction: Challenge:	0.01 0.01	1/ 20	Ritz-Buehler	Bay and Danneman 1985b
26.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS sample)	Induction: Challenge:	0.01 0.01	5/20	Ritz-Buehler	Bay and Danneman 1985b
27.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS sample)	Induction: Challenge:	0.01 0.01	5/20	Ritz-Buehler	Bay and Danneman 1985b
28.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS sample)	Induction: Challenge:	0.11 0.01	8/20	Ritz-Buehler	Bay and Danneman 1985b

(Continued on next page)

Table 2. Guinea pig sensitization studies on sultones (Arthur D. Little, Inc. 1993) (*continued*)

No.	Sultone type	Concentration (ppm)	Sensitization rate	Comment/technique	Reference	
29.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS sample)	Induction: Challenge:	0.24 0.01	4/20	Ritz-Buehler	Bay and Danneman 1985b
30.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS sample)	Induction: Challenge:	0.09 0.05	3/20	Ritz-Buehler; AOS sample analyzed using HPLC or tandem mass spectrometry	Bay and Danneman 1985b
31.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS sample)	Induction: Challenge:	0.02 0.01	1/20	Ritz-Buehler; AOS sample analyzed using HPLC or tandem mass spectrometry	Bay and Danneman 1985b
32.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS sample)	Induction: Challenge:	0.09 0.01	3/20	Ritz-Buehler	Bay and Danneman 1985b
33.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS containing liquid laundry detergent)	Induction: Challenge:	0.04 0.02	2/20	Ritz-Buehler; ppm calculated	Bay and Danneman 1985b
34.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS containing "consumer product")	Induction: Challenge:	0.21 0.10	8/20	Ritz-Buehler; ppm calculated	Bay and Danneman 1985b
35.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS containing "consumer product")	Induction: Challenge:	0.12 0.05	1/20	Ritz-Buehler; ppm calculated	Bay and Danneman 1985b

36.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS containing "consumer product")	Induction: Challenge:	0.39 0.19	7/20	Ritz-Buehler; ppm calculated	Bay and Danneman 1985b
37.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS containing light duty liquid laundry detergent; <u>bleach added</u>)	Induction: Challenge:	0.1 0.1	1/20	Modified Ritz Buehler; ppm calculated	Bay and Danneman 1985b
38.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS containing light duty liquid laundry detergent; <u>bleach added</u>)	Induction: Challenge:	22.0 6.1	11/20	Modified Ritz Buehler; ppm calculated	Bay and Danneman 1985b
39.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS containing light duty liquid laundry detergent; <u>bleach added</u>)	Induction: Challenge:	122.2 11.0	2/9	Modified Ritz Buehler; ppm calculated	Bay and Danneman 1985b
40.	Combination of unsaturated gamma C ₁₂ , C ₁₄ , and C ₁₆ sultones (in an AOS containing light duty liquid laundry detergent; <u>bleach added</u>)	Induction: Challenge:	122.2 11.0	5/9	Modified Ritz Buehler; ppm calculated. Study repeated; same results	Bay and Danneman 1985b
41.	1-Tetradecene-1,3-sultone	Induction: Challenge: Rechallenge:	10 10 0.1 50	0/15 0/15 0/15	Buehler	Inveresk Research International 1985

(Continued on next page)

Table 2. Guinea pig sensitization studies on sultones (Arthur D. Little, Inc. 1993) (*continued*)

No.	Sultone type	Concentration (ppm)	Sensitization rate	Comment/technique	Reference
42.	1-Tetradecene-1,3-sultone	Induction: Challenge:	1 50 1 0/15 0/15	Buehler	Inveresk Research International 1985
43.	1-Tetradecene-1,3-sultone	Induction: Challenge:	0.1 50 0.01 0/15 0/15	Buehler	Inveresk Research International 1985
44.	1-Tetradecene-1,3-sultone	Induction: Challenge:	0.01 50 5 0/15 0/15	Buehler	Inveresk Research International 1985
45.	1-Dodecene-1,3-sultone	Induction: Challenge:	4,000 (0.4%) 100 (0.01 %) 10 (0.001%) 10/15 5/15 2/15	Closed patch	CTFA 1995b
46.	1-Dodecene-1,3-sultone	Induction: Challenge: Rechallenge:	1 18 2 4 2 1 0.5 0.25 17/23 5/5 6/6 5/5 5/6 3/5	Injection	CTFA 1995b

unbleached, 10% active C_{14-16} AOS (2:1) and bleached 10% active C_{14-16} sensitized 5/10 and 6/10 animals, respectively. Sensitization was attributed to incomplete hydrolysis, but follow-up studies ruled out saponification and/or the presence of saturated sultones or residual oil as the causes. Two other bleached C_{14-16} AOS samples were also unexplained sensitizers. One of the two samples sensitized 7/10 guinea pigs in the first trial, but the results could not be duplicated. The seventh sample, C_{14-16} AOS (3:2) paste (29.4% active), sensitized 10/19 guinea pigs challenged with a 10% dilution; 5/10 had positive reactions with a 5% challenge. Similar findings were noted with a C_{16-18} (55:45) AOS paste (25.7% active) where positive reactions were noted in 2/20, 8/20, and 10/20 animals challenged with 7.5%, 15%, and 20%, respectively. In the ninth sample, repeated topical application of undiluted C_{16-18} sensitized 10/20 guinea pigs challenged with a 20% aqueous solution.

REPRODUCTIVE AND DEVELOPMENTAL TOXICITY

Palmer, Readshaw, and Neuff (1975) tested the teratogenic potential of C_{14-18} AOS using pregnant rats (20/dose), mice (20/dose), and rabbits (13/dose). The strains of animals used were not reported. Mice and rats were treated by gavage on days 6–15 of gestation; rabbits were treated on days 6–18. Doses were 0.2, 2, 300, and 600 mg/kg/day (the sultone content is unknown). No signs of maternal toxicity were observed in any of the treated rats. All rabbits given 600 mg/kg died; one dam of the 300 mg/kg group died. Anorexia, diarrhea, and body weight loss were observed prior to death. Six mice treated with 600 mg/kg died; five dams of this treatment group lost their litters. Six dams of the 300 mg/kg group lost their litters. Both mice and rabbits of the 0.2 and 2.0 mg/kg dose groups had initial reduction in body weight gain. Litter parameters (litter size, embryonic deaths, litter weight, mean pup weight) were unaffected at doses of 0.2 and 2.0 mg/kg in mice and rabbits and in all treated rats. No effects on the litters were noted at doses that were non-toxic or slightly toxic to dams. When total litter loss data were excluded, litter size and embryonic loss values for mice and rabbits of the two highest dose groups were comparable to control values. Pups of rabbits from the 300 mg/kg and pups of mice from the 600 mg/kg treatment group had lower (though not significant) mean body weight. At all doses of AOS, litter and mean pup weights of mice were lower than those of concurrent controls. However, the weights of pups of the treated groups were within the range for historical controls. Fetal abnormalities were noted in mice and rabbits at doses where maternal toxicity was noted. The incidence of minor skeletal anomalies in pups was high in rabbits of the 300 mg/kg group (23% vs. 7% for controls), and the proportion

of pups having an extra rib was significantly larger (87% vs. 59% for controls). There were no pups to examine from the 600 mg/kg group. In mice, cleft palates were observed in four pups of the 600 mg/kg group and in two of the 300 mg/kg group. (There was an exencephalic control pup.) A significantly high incidence of skeletal anomalies (mostly retarded ossification) was seen in pups of the 600 mg/kg group. However, it was stressed that the 1.0% incidence of abnormalities in controls was unusually low.

MUTAGENICITY

The reviews by the Soap and Detergent Association (Arthur D. Little, Inc. 1993) and by Oba and Takei (1992) cite several mutagenicity tests done using bacterial strains. Table 3 summarizes these tests. With one exception, all the tests were negative. In the exception, 283 mg/kg of C₁₄₋₁₆ AOS (28.4% active) was mutagenic to *Salmonella typhimurium* TA 1530 (a point mutation) when tested in a rat host-mediated assay. (In a host-mediated assay, the animal is injected intraperitoneally with the bacterial strain and then immediately treated with the test substance via an intramuscular injection. After dosing, saline is injected intraperitoneally, and the fluid is withdrawn from the peritoneal cavity of the host. The mutation frequency in the recovered microorganisms is measured by counting viability [Oba and Takei 1992].) However, the Soap and Detergent Association review reported that in vitro assays with up to 1% C₁₄₋₁₆ AOS were negative for the strain. Further, when the pH of the original test sample was neutralized and readjusted, a negative response was obtained in the host-mediated assay. The original sample was then extracted in ether and the aqueous fraction obtained was retested (210 mg/kg). The number of revertants was reduced from 1202 and >10,000 (two experiments) for the original sample to 477 revertants with the washed sample (Arthur D. Little, Inc. 1993).

CARCINOGENICITY

Hunter and Benson (1976) conducted a 104-week feeding study using CFY rats. The AOS used in the study was a mixture of alkenyl sulfonate and hydroxyalkane sulfonate present in a 60.4 : 39.6% ratio. The mixture was administered at dietary concentrations of 1000, 2500, and 5000 ppm to groups of 50 male and 50 female rats. No significant treatment-related differences were observed in the overall incidence of neoplasms, whether malignant or benign, between treated and control groups.

Table 3. Bacterial mutagenicity testing

AOS concentration (max.)	Assay (if indicated)	Strain tested	Result	Reference
<i>In vitro</i>				
10,000 ppm	Reversion Plate	<i>Salmonella typhimurium</i> TA 1535, 1536, 1537, 1538 <i>Esherichia coli</i> B/r WP try and try her	Negative (strains 1536 and 1538 had smaller colony size than His + strains but were <i>not</i> revertants)	Oba and Takei 1992
100 μ g/plate	Ames	<i>S. typhimurium</i> TA 98, 100, 1535, 1537, 1538	Negative	Oba and Takei 1992
100 μ g		<i>S. typhimurium</i> TA 98, 100	Negative	Oba and Takei 1992
2 mg/plate		<i>S. typhimurium</i> TA 1535, 1536, 1537, 1538 (7 preparations) <i>S. typhimurium</i> TA 1535 (4 AOS compounds tested)	Negative	Arthur D. Little, Inc. 1993
<i>In vivo</i>				
283 mg/kg AOS C ₁₄₋₁₆ (28.4% active)	Host-mediated (rat)	<i>S. typhimurium</i> TA 1530, 1534	(+) in TA1530 (see text) (-) in TA 1534	Arthur D. Little, Inc. 1993
i.m. 0.1 ml/1% solution	Host-mediated (mouse)	<i>S. typhimurium</i> TA 1535	Negative	Oba and Takei 1992

Sultones have been proposed as potential carcinogens in laboratory animals (Slaga et al. 1973).

A skin painting study involving Swiss Webster mice was used to test AOS and C₁₆ 1,4-sultone. Treatment groups (40/sex/group) were as follows: (1) 20% AOS (based on C₁₄₋₁₈ α -olefin); (2) 25% AOS (from supplier used in Group 1); (3) 20% AOS (based on C₁₄₋₁₆ α -olefin from another supplier); (4) 25% AOS (from supplier used in Group 3); (5) 6.7% C₁₆ 1,4-sultone in acetone; (6) 8.3% C₁₆ 1,4-sultone in acetone; (7) untreated control (shaved only); (8) water control; and (9) Acetone control. The test substance (0.02 ml) was applied to the interscapular region, three times a week for 92 weeks. Mean survival rate per group was 30%. Necropsy was performed. No toxic or carcinogenic effects of the two AOS products and sultone were observed in the skin painting study (Oba and Takei 1992).

A feeding study was also conducted using 11 groups of 40 male and 40 female MRC rats (Wistar derived). Treatment groups were as follows: (1) untreated control; (2) 1.0% AOS (based on C₁₄₋₁₈ α -olefin); (3) 0.75% AOS (from supplier used in Group 2); (4) 0.5% AOS (from supplier used in Group 2); (5) 1.0% AOS (based on C₁₄₋₁₆ from another supplier); (6) 0.75% AOS (from supplier used in Group 5); (7) 0.5% AOS (from supplier used in Group 5); (8) 0.33% C₁₆ 1,4-sultone; (9) 0.25% C₁₆ 1,4-sultone; (10) 0.16% C₁₆ 1,4-sultone; and (11) extra control. The experiment was terminated when a mean survival point of 50% was reached. No toxic or carcinogenic effects related to treatment with AOS or sultone were observed (Oba and Takei 1992).

In a 92-week dermal exposure study, groups of Swiss Webster mice (40/sex) were treated three times a week with 0.02 ml of one of the following six treatments: (1) 20% C₁₄₋₁₈ AOS; (2) 25% C₁₄₋₁₈ AOS; (3) 20% C₁₄₋₁₆ AOS; (4) 25% C₁₄₋₁₆ AOS; (5) 6.7% C₁₆ 1,4-sultone; and (6) 8.3% C₁₆ 1,4-sultone. No significant toxicity or lesions attributable to AOS treatment were noted (Arthur D. Little, Inc. 1993).

In a 2-year dermal exposure study, groups of Long-Evans rats (50/sex/group) were treated with the following: (1) deionized water (vehicle control); (2) hydrolyzed, composite sample of C₁₄₋₁₆ AOS and C₁₆₋₁₈ AOS (30.0% active); (3) partially hydrolyzed sample of AOS, (same as Group 2 but containing residual level of sultone); and (4) commercial C₁₄₋₁₆ AOS (38.9% active). The test substance was applied twice weekly to the clipped dorsal surface as a 10% active (v/v) aqueous solution at a dose of 1 ml/kg. Mean body weights, feed consumption, hematology, urinalysis, mortality, and gross lesions were comparable for all groups. Group 2 males had a slightly lower mean kidney weight and a significantly lower mean kidney to body weight ratio as compared to controls. The tests were negative for a carcinogenic effect attributable to the percutaneous application of the AOS test materials (Bio/Dynamics Inc. 1979).

Another study (Oba and Takei 1992) noted occasional dermatitis in Swiss-Webster mice (21 animals/group) treated for 2 years with twice-weekly applications of 5% aqueous solutions of either: (1) C₁₅₋₁₈ AOS (90% active); (2) hexadecane 1,4-sultone; or (3) sultone concentrate (64% active) extracted from the sulfonation process of an α -olefin.

CLINICAL ASSESSMENT OF SAFETY

Dermal Irritation and Sensitization

Magnusson and Gilje (1973) reported an outbreak of sensitization to a dishwashing detergent in Norway in the late 1960s. It was later established that ~ 22 ppm of unsaturated sultones was in the finished product (Connor et al. 1975). In a review of these findings, it was noted that the actual use exposure (allowing for a 500-fold dilution) was 0.044 ppm unsaturated sultones.

Bay and Danneman (1985a) reported that in a sensitization test, sodium C₁₄₋₁₆ AOS paste and an AOS-containing dishwashing detergent did not induce sensitization in >900 panelists. AOS was tested at a maximum concentration of 0.06% with up to 0.002 ppm unsaturated sultones as an impurity. Although no induction of sensitization was observed, one case of pre-existing sensitization was detected. This individual reacted to a detergent containing ~0.002 ppm unsaturated sultones under patch and was positive to an AOS paste on rechallenge. The results from this individual helped to establish an elicitation threshold for unsaturated sultones of 0.002 ppm under patch test conditions (Bay and Danneman 1985b).

Bay and Danneman (1985a, b) also reported that in diagnostic patch tests conducted using 542 panelists who had previous exposure to AOS-containing products, 15 had positive responses to 1.3 ppm unsaturated sultones in 0.046% sodium lauryl sulfate. None of the 15 patch-positive panelists reported any clinically significant skin problems following use of AOS (sultone)-containing products. Nonetheless, the results of the study suggested the possibility of pre-existing subclinical sensitization to unsaturated sultones, potentially attributable to consumer products containing low concentrations (<0.01–4.8 ppm).

In a separate product use test, sensitization to unsaturated sultones was induced and elicited in 2 of 264 subjects with no prior AOS exposure, after using an AOS-containing dishwashing detergent. Both developed hand dermatitis after use of the product; none of the 248 control subjects using a non-AOS detergent had hand dermatitis. The undiluted AOS detergent contained 0.5–1 ppm unsaturated sultones with in-use exposure at concentrations ~500-fold lower (Bay and Danneman 1985a, b).

In one unpublished study cited in the review by the Soap and Detergent Association (Arthur D. Little, Inc. 1993), 1 and 2% concentrations of AOS were nonirritating after 24-hour patch testing. In another study, 1 and 5% AOS were mild irritants, with reactions ranging from erythema to fissure formation accompanied by scaling. A 10-day occlusive patch test with 0.8% active AOS resulted in increasing irritation as the study continued.

In immersion studies, concentrations of 0.3% AOS caused negligible irritation following 30 1-minute immersions done in the course of 1 hour, and a 0.04% effective concentration of AOS (in a detergent formulation) was classified as a mild irritant after three 15-minute immersions done for up to 15 days. Half of the panelists were able to complete 12 immersions before reaching the predetermined irritation level (a score of "2") (Arthur D. Little, Inc. 1993).

Ter Haar (1983) reported no contact sensitization when 88 men were treated with an 8% aqueous AOS solution (occlusive patch applied three times a week for a total of 10 induction applications) and then challenged 2 weeks later with 4% AOS. (The challenge dose was reduced because of severe irritation.) Ter Haar (1983) also reported that sensitization occurred in 8 of 195 panelists treated three times a week for three weeks with 1% AOS (containing 28 ppm 1,3-sultones) and then challenged after a 1-week nontreatment period. Five of these eight reactors were also challenged with AOS containing 1 ppm of 1,3-sultone; 3/5 had positive reactions.

SUMMARY

Sodium AOS are a mixture of sodium alkene sulfonates and sodium hydroxyalkane sulfonates. Care should be taken in their manufacture to avoid producing alkene sultones and chlorosultones, some of which are potent sensitizers.

AOS are approved for use as indirect food additives. They function as surfactant-cleansing agents in cosmetic formulations. As of January 1996, there were 93 reported uses of sodium C₁₄₋₁₆ olefin sulfonates.

AOS are rapidly absorbed, metabolized, and excreted (primarily in the urine) following oral or intravenous exposure. Dermal absorption was increased when AOS was applied to damaged skin.

Acute oral LD₅₀ values for AOS range from 1300–2400 mg/kg in rats and 2500–4300 mg/kg in mice. No treatment related changes were noted in rats following a single 1-hour inhalation exposure to either an AOS flake (90% active) or a 17% AOS formulation, or after repeated exposure to 0.9 or 10% C₁₄₋₁₆ AOS.

In a 7-day oral study in rats, the "no effect" dose was between 0.625 and 1.25%. One 91-day study noted hematologic changes in rats which

received up to 500 mg/kg of either C₁₄₋₁₆ AOS or C₁₆₋₁₈ AOS (both 34% active). In another 90-day oral study, a slight increase in the liver to total body weight ratio was found in animals of the highest dose group, 1000 mg/kg/day, but no changes in hematologic parameters were found at any dose. Concentrations of $\geq 10\%$ AOS are moderately to severely irritating to rabbit eyes. In one study, mild irritation occurred after exposure to 5% C₁₄₋₁₉ AOS.

Dermal irritation studies have recorded mild to moderate skin irritation in guinea pigs and rabbits after repeated exposure to $\geq 2\%$ AOS of varying carbon lengths. Nine of 64 AOS samples produced sensitization in guinea pigs; in some, but not all cases, sensitization was attributed to the presence of unsaturated and chloro-1,3-sultones.

In teratogenicity studies, no signs of maternal toxicity or reproductive effects were found in pregnant rats treated with up to 600 mg/kg of C₁₄₋₁₈ AOS on days 6-15 of gestation. Maternal toxicity and litter loss were observed in some mice and rabbits given 300 and 600 mg/kg; litter parameters were unaffected in mice and rabbits given 0.2 and 2.0 mg/kg. Fetal abnormalities were observed at treatment doses producing maternal toxicity.

With one exception, all mutagenicity assays conducted on AOS were negative. In the exception, 283 mg/kg of C₁₄₋₁₆ AOS was mutagenic in a host-mediated assay conducted using rats; however, when the sample was neutralized or extracted in ether, the mutagenic capacity was diminished. Various oral and dermal carcinogenicity studies were negative.

Various clinical studies found irritation to AOS and sensitization to very low levels of sultones.

DISCUSSION

The Cosmetic Ingredient Review (CIR) Expert Panel was satisfied with results of toxicity, mutagenicity, carcinogenicity, and reproductive/developmental studies cited in this report. The focus of the Panel's safety assessment of sodium AOS concerned the sensitizing potential of sultone impurities as indicated by guinea pig studies in Table 2.

Delta sultones (1,4-sultones) either in pure unsubstituted form (studies 1-3 in Table 2) or as a chlorosultone (Study 11 in Table 2) did not induce sensitization in Magnusson-Kligman maximization assays. Further, it is believed that AOS preparations contain 1,4-sultones at sufficiently low concentrations (<34 ppm) such that sensitization is not of concern.

Studies indicated that gamma sultones (1,3-sultones) were potent sensitizers at very small concentrations, though there was marked difference in the sensitization potential of the various gamma sultone types: unsubstituted alkane, chloro, and unsaturated (alkene).

With regard to unsubstituted alkane gamma sultones, studies employing either the Magnusson-Kligman (Study 8 in Table 2) or an injection technique (Study 10 in Table 2) indicated that a 2% induction concentration can induce sensitization. As no data were received regarding sensitization potential at lower induction concentrations, and a re-challenge concentration of 100 ppm elicited a response in virtually all animals tested (Study 8 in Table 2), the Panel elected to impose a significant safety factor and limit unsubstituted alkane gamma sultone concentrations to ≤ 10 ppm.

Gamma chlorosultones tested under either the Magnusson-Kligman (Study 12 in Table 2) or an injection technique (Study 13 in Table 2) indicated that 20 ppm was a sensitizer. No data were available on the sensitizing potential of gamma chlorosultones at induction concentrations less than 20 ppm. It was noted that Study 14 (in Table 2) which employed a closed-patch technique demonstrated a low response to challenge concentrations of 1.2 ppm following induction with 4,000 ppm. In view of these findings, the Expert Panel imposed a safety factor and limited gamma chlorosultone concentrations to ≤ 1 ppm.

With regard to unsaturated gamma sultones, it was noted that clinical safety data demonstrated induction/elicitation thresholds as low as 0.001–0.002 ppm (calculated but not measured) under certain conditions (Bay and Danneman 1985b). However, the Panel acknowledged that there has been only one clinically relevant sultone sensitization incident reported in the literature, despite broad use of AOS in the marketplace. In determining levels of safety for unsaturated gamma sultones, the CIR Expert Panel relied on Studies 17–24 (in Table 2) by Inveresk Research International (1985), which used the Magnusson-Kligman technique and demonstrated a dose-dependent response. In Studies 22 and 23 (in Table 2) no sensitization was produced by an induction concentration of 0.01 ppm. Sensitization was noted at 1 ppm, which was the next induction concentration tested (Study 21 in Table 2). Although additional studies using the Buehler technique demonstrated nonsensitization at higher induction concentrations (Studies 41–43 in Table 2), the Panel elected to use studies which employed the Magnusson-Kligman technique. In light of the sensitizing capacity of unsaturated gamma sultone at such small levels, the Panel was of the opinion that the stringent conditions of the Magnusson-Kligman technique (which combines injection and topical induction exposures) allowed for a more reliable measure of safety. Based on these data, the Expert Panel limited unsaturated gamma sultone concentrations to ≤ 0.1 ppm.

With the above limitations to guide manufacturers, the ability of certain gamma sultones to sensitize at very low concentrations remains. Thus, the Panel alerted producers of sodium α -olefin sulfonates to the possibility that testing in biological systems could be done in order

to make certain that commercially supplied preparations are not sensitizing.

The Panel acknowledged that because these ingredients are detergents, they would most likely be used in rinse-off products. Sodium AOS were considered to be safe for use in rinse-off products (provided gamma sultone impurities are limited to the above concentrations).

The Panel imposed a concentration limit of 2% in leave-on products, based on animal dermal irritation studies (provided gamma sultone impurities are limited to the above concentrations). A concentration of 2% aqueous C₁₆₋₁₈ AOS produced nil-to-slight irritation in guinea pigs after nine dermal applications.

CONCLUSION

Based on the available data, the CIR Expert Panel concludes Sodium α -Olefin Sulfonates (of chain lengths C₁₂₋₁₄, C₁₄₋₁₆, C₁₄₋₁₈, and C₁₆₋₁₈) to be safe as used in rinse-off products and safe up to 2% in leave-on products. The concentration of the gamma sultone impurity of any formulation (leave-on or rinse-off) is limited to unsubstituted alkane sultones ≤ 10 ppm; chlorosultones ≤ 1 ppm; and unsaturated sultones ≤ 0.1 ppm.

REFERENCES

- Arthur D. Little, Inc. 1993. Environmental and human safety of major surfactants, Volume 1. Anionic surfactants. Part 4. Alpha Olefin Sulfonates. National Technical Service (NTIS) report No. PB94-102423.
- Bay, P. H. S., and P. J. Danneman. 1985a. Skin sensitization potential of alpha-olefins (AOS) and a prototype dishwashing detergent containing AOS. *J. Am. Oil Chem. Soc.* 62:646.
- Bay, P. H. S., and P. J. Danneman. 1985b. Delayed contact skin sensitization tests of alpha olefin sulfonate alone and in a dishwashing liquid. Presented at the AOCS meeting, Philadelphia, PA, May 1985. Unpublished data submitted by the Cosmetic, Toiletry and Fragrance Association, August 8, 1995. (22 pages.)¹
- Bio/Dynamics Inc. 1979. A twenty-four month dermal carcinogenicity study of experimental sulfonated compounds in rats. Project No. 74-1094. (Submitted by FDA in response to an FOI request—1994.)
- Connor, D. S., H. C. Ritz, R. S. Ampulski, H. G. Kowollik, P. Lim, D. W. Thomas, and R. Parkhurst. 1975. Identification of certain sultones as the sensitizers in an alkyl ethoxy sulfate. *Fette Seifen Anstrichmittel* 77:25-29.

¹Available for review: Director, CIR, 1101 17th Street, NW, Suite 310, Washington, DC 20036, USA.

- Cosmetic, Toiletry, and Fragrance Association (CTFA). 1981. Eye irritation: Alpha olefin sulfonates. Test#: 48-191 and 48-193. Unpublished data submitted by CTFA, June 20, 1995. (2 pages.)¹
- CTFA. 1995. Use levels for various ingredients. Unpublished data submitted by CTFA, July 17, 1995. (2 pages concerning Alpha-Olefin Sulfonates.)¹
- CTFA. 1995b. Submission requesting a revision of the May 23, 1995 tentative conclusion on Alpha-Olefin Sulfonates. Unpublished data submitted by CTFA, August 8, 1995. (11 pages.)¹
- Food and Drug Administration (FDA). 1992. Modification in Voluntary Filing of Cosmetic Product Ingredient and Cosmetic Raw Composition Statements. Final rule. *Fed. Register* 57:3128–3130.
- FDA. 1996. Frequency of use of cosmetic products. *FDA database*. Washington, D.C.: FDA.
- Goodwin, B. F. J., D. W. Roberts, D. L. Williams, and A. W. Johnson. 1983. Skin sensitization potential of saturated and unsaturated sultones, In *Immunotoxicology*, 443–448. London: Academic Press.
- Hunter, B., and H. G. Benson. 1976. Long-term toxicity of the surfactant α -olefin sulphonate (AOS) in the rat. *Toxicology* 5:359–370.
- Inoue, S., J. S. O' Grodnick, and S. Tomizawa. 1982. Metabolism of α -olefin sulfonate (AOS) in rats. *Fundam. Appl. Toxicol.* 2:130–138.
- Imori, M., T. Ogata, and K. Kudo. 1972a. Irritation of the ocular mucosa of rabbits by surfactants. *Yukagaku* 21:46–49.
- Imori, M., T. Ogata, and K. Kudo. 1972b. Eye irritation tests with surfactants on experimental animals. *Yukagaku* 21:334–337.
- Inveresk Research International. 1985. Sodium alpha-olefin sulfonates: An impurity: a Magnusson-Kligman maximization test in guinea pigs. Unpublished data submitted by Lion Corporation, March 11, 1996. (4 pages.)¹
- Kirk-Othmer. 1983. *Encyclopedia of chemical technology*. 3rd ed., Vol. 22, 15–18.
- Lewis, R. J., Sr. 1993. *Hawley's condensed chemical dictionary*. 12th ed. New York: Van Nostrand Reinhold Co.
- MacMillan, W. D., and H. V. Wright. 1977. Determination of sultones in anionic surfactants. *J. Am. Oil Chem. Soc.* 54:163–166.
- Magnusson, B., and O. Gilje. 1973. Allergic contact dermatitis from a dish-washing liquid containing lauryl ether sulphate. *Acta Dermatovener* 53:136–140.
- Matsutani, S., H. Tsuchikane, T. Sugiyama, and T. Nagai. 1986. Determination of 1-alkene-1,3-sultones in anionic surfactants by gas chromatography-mass spectrometry. *Yukagaku* 35:80–84.
- Minegishi, K. I., M. Osawa, and T. Yamaha. 1977. Percutaneous absorption of α -olefin sulfonate (AOS) in rats. *Chem. Pharm. Bull. (Tokyo)* 25:821–825.
- Oba, K., and R. Takei. 1992. Carcinogenic, mutagenic/genetic toxicity, and teratogenic properties. In *Anionic surfactants; biochemistry, toxicology and dermatology*. 2nd ed. *Surfactant science series*. Vol. 43. Eds. C. Gloxhuber and K. K nstler, 331–409. New York: Marcel Dekker.
- Palmer, A. K., M. A. Readshaw, and A. M. Neuff. 1975. Assessment of the teratogenic potential of surfactants. Part II—AOS. *Toxicol.* 3:107–113.

- Rempe, J. M., and L. G. Santucci, eds. 1992. *CTFA list of Japanese cosmetic ingredients*. 2nd ed. Washington, D.C.: The Cosmetic, Toiletry and Fragrance Association.
- Ritz, H. I., D. S. Connor, and E. D. Sauter. 1975. Contact sensitization of guinea pigs with unsaturated and halogenated sultones. *Contact Dermatitis* 1:349–358.
- Roberts, D. W., and D. L. Williams. 1983. Sultones as by-products in anionic surfactants. *Tenside* 20:109–111.
- Roberts, D. W., J. G. Lawrence, L. A. Fairweather, C. J. Clemett, and C. D. Saul. 1987. An investigation into the possibilities of formation of alk-1-ene-1,3-sultones in alpha olefin sulfonates (AOS). *J. Com. Esp. Deterg.* 18:101–117.
- Rothschild, D. L. 1990. *The Food Chemical News Guide to the current status of food additives and color additives*, 302.6. Washington, D.C.: Rothschild.
- Schoenberg, T. G. 1980. Formulating C14-16 alpha olefin sulfonates in high foaming shampoos. *Soap/Cosmetics/Chemical Specialties* May:54–62.
- Slaga, T. J., G. T. Bowden, B. G. Shapas, and R. K. Boutwell. 1973. Macromolecular synthesis following a single application of alkylating agents used as initiators of mouse skin tumorigenesis. *Cancer Res.* 33:769–776.
- Stepan Company. 1995. Personal communication (letter dated June 7, 1995) from Dave Rapson, Assistant Director, Corporate Quality Assurance to Dr. G. N. McEwen, Jr. at CTFA.¹
- Ter Haar, G. 1983. AOS—the safety of alpha olefin sulfonates. *Household and Personal Products Industry* 20:54–56.
- Wenninger, J. A., and G. N. McEwen, eds. 1995a. *International cosmetic ingredient dictionary*. 6th ed., 925–926. Washington, D.C.: The Cosmetic, Toiletry and Fragrance Association, Inc.
- Wenninger, J. A., and G. N. McEwen, eds. 1995b. *CTFA cosmetic ingredient handbook*. 3rd ed., 663. Washington, D.C.: Cosmetic, Toiletry, and Fragrance Association (CTFA).
- Yakuji Nippo, Ltd. 1994. *The comprehensive licensing standards of cosmetics by category 1994 (CLS 1994)*, 104 to 105. Tokyo, Japan: Yakuji Nippo, Ltd.